Name
GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053: A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer - Commentary by Sheldon Feldman, MD, FACS
Date & Time
Wednesday, December 3, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL